Company profile
Anika Therapeutics, Inc.
NASDAQ: ANIK · Healthcare · Medical - Devices
PublicHQ Bedford, MACIK 0000898437Reports USD
#337 of 1,418 Healthcare companies by revenue34th-percentile growth
EA Score
74BFH 75DQ 83GM 47SS 80
v0.1 · 65/100 weight · provisional
↑ listing tenure, disclosure history · ↓ 3-yr revenue growth, revenue growth (YoY)
Methodology →Revenue TTM
$116.3M
Rev growth YoY (TTM)
+23.2%
Net income (FY)
-$10.9M
Employees
235
as of 2026-08-13
Market cap
$294.8M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$112.8M$112.8M2025
Net income-$10.9M-$10.9M2025
Operating income-$11.1M-$11.1M2025
Total assets$190.3M$190.3M2025
Equity$143.5M$143.5M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Anika Therapeutics, Inc.’s revenue?
Anika Therapeutics, Inc. booked $112.8M in FY2025 revenue, contracting 5.9% year over year — slower than 66% of Healthcare companies we track, at a -9.6% net margin.
Peers · Healthcare
OraSure Technologies, Inc.67BAgenus Inc.67BImmunityBio, Inc.58CUroGen Pharma Ltd.55COptimizeRx Corp.72BCentury Therapeutics, Inc.48DKey facts
CEOStephen D. Griffin
SectorHealthcare
IndustryMedical - Devices
HeadquartersBedford, MA
ExchangeNASDAQ: ANIK
Employees235
IPO date1993-05-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.